Arrowhead Pharmaceuticals (ARWR) Insider Trading & Ownership $14.42 +0.38 (+2.71%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$14.38 -0.04 (-0.31%) As of 05/2/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.30%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$7.23 M Get ARWR Insider Trade Alerts Want to know when executives and insiders are buying or selling Arrowhead Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ARWR Insider Buying and Selling by Quarter Arrowhead Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/11/2025Christopher Richard AnzaloneCEOSell50,800$11.49$583,692.00 4/9/2025Christopher Richard AnzaloneCEOSell40,322$10.07$406,042.54 3/13/2025Christopher Richard AnzaloneCEOSell51,425$15.07$774,974.75 3/4/2025Christopher Richard AnzaloneCEOSell133,333$17.02$2,269,327.66 1/23/2025Adeoye Y OlukotunDirectorSell959$21.00$20,139.00 1/6/2025James C HamiltonInsiderSell32,729$19.82$648,688.78 1/6/2025Kenneth Allen MyszkowskiCFOSell27,167$19.83$538,721.61 1/6/2025Patrick O'brienCOOSell29,184$19.82$578,426.88 1/2/2025Christopher Richard AnzaloneCEOSell11,520$19.05$219,456.00 12/27/2024Adeoye Y OlukotunDirectorSell2,850$20.00$57,000.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/23/2024Christopher Richard AnzaloneCEOSell12,563$19.59$246,109.17 12/18/2024Christopher Richard AnzaloneCEOSell26,712$21.24$567,362.88 12/16/2024William D WaddillDirectorSell3,748$21.90$82,081.20 7/2/2024Tracie OliverInsiderSell9,394$25.28$237,480.32 (Data available from 1/1/2013 forward) ARWR Insider Trading Activity - Frequently Asked Questions Who is on Arrowhead Pharmaceuticals's Insider Roster? The list of insiders at Arrowhead Pharmaceuticals includes Adeoye Y Olukotun, Christopher Richard Anzalone, Douglas B Given, Hongbo Lu, James C Hamilton, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, Tracie Oliver, Victoria Vakiener, and William D Waddill. Learn more on insiders at ARWR. What percentage of Arrowhead Pharmaceuticals stock is owned by insiders? 4.30% of Arrowhead Pharmaceuticals stock is owned by insiders. Learn more on ARWR's insider holdings. Which Arrowhead Pharmaceuticals insiders have been buying company stock? The following insider purchased ARWR shares in the last 24 months: Hongbo Lu ($54,990.00). How much insider buying is happening at Arrowhead Pharmaceuticals? Insiders have purchased a total of 2,000 ARWR shares in the last 24 months for a total of $54,990.00 bought. Which Arrowhead Pharmaceuticals insiders have been selling company stock? The following insiders have sold ARWR shares in the last 24 months: Adeoye Y Olukotun ($77,139.00), Christopher Richard Anzalone ($11,941,324.67), Douglas B Given ($376,642.66), James C Hamilton ($2,381,773.12), Kenneth Allen Myszkowski ($3,057,309.69), Martin Javier San ($567,360.00), Patrick O'brien ($1,666,446.67), Tracie Oliver ($552,622.07), Victoria Vakiener ($82,746.19), and William D Waddill ($82,081.20). How much insider selling is happening at Arrowhead Pharmaceuticals? Insiders have sold a total of 842,640 Arrowhead Pharmaceuticals shares in the last 24 months for a total of $20,785,445.27 sold. Arrowhead Pharmaceuticals Key ExecutivesDr. Christopher R. Anzalone Ph.D. (Age 55)CEO, President & Director Compensation: $1.6MMr. Kenneth A. Myszkowski (Age 58)Chief Financial Officer Compensation: $834.34k1 recent tradesMr. Patrick O'Brien J.D. (Age 60)PharmD, COO, General Counsel & Secretary Compensation: $835.14kDr. James C. Hamilton M.D. (Age 46)MBA, Chief of Discovery & Translational Medicine Compensation: $762.14kDr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & CalandoDr. Vincent Anzalone CFAHead of Investor Relations & VPMr. Howard LovyDirector of CommunicationsDr. Bruce D. Given M.D. (Age 70)Chief Medical Scientist Compensation: $486.31kDr. Mark Seefeld (Age 70)Head of Toxicology & VP Ms. Tracie Oliver (Age 62)Chief Commercial Officer Compensation: $449.58k More Insider Trading Tools from MarketBeat Related Companies Lantheus Insider Selling BridgeBio Pharma Insider Selling TG Therapeutics Insider Selling Sarepta Therapeutics Insider Selling ADMA Biologics Insider Selling Blueprint Medicines Insider Selling Verona Pharma Insider Selling Nuvalent Insider Selling Axsome Therapeutics Insider Selling Grifols Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles McDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why This page (NASDAQ:ARWR) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARWR Stock Free ARWR Stock Alerts